MADRID, October 4, 2017 /PRNewswire/ --
PharmaMar (MCE: PHM) announces submission of the Marketing Authorisation Application to the Swiss Agency for Therapeutic Products (Swissmedic) for Aplidin® for the treatment of patients with multiple myeloma.
(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
The regulatory process for an oncological drug in Switzerland is independent from that of the European Medicines Agency´s process (EMEA), to which PharmaMar submitted the corresponding application at the end of 2016.
Aplidin® was designated orphan drug status by Swissmedic, the European Commission and also the Food and Drug Administration (FDA). In the European Union, this status is granted for the compounds that are investigated for the treatment of illnesses that affect 5 per 10,000 inhabitants or less. This gives the sponsor a series of incentives, among which are included the possibility of a priority evaluation by Swissmedic, the regulatory authority in Switzerland.
The submission of this application represents a milestone for PharmaMar. "We have obtained positive results with this molecule in the pivotal phase III study and we believe that Aplidin® could be a novel therapeutic alternative for patients with multiple myeloma that live in Switzerland," said Luis Mora, Managing Director at the Oncology Business Unit at PharmaMar.
Contact: Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500)
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...View All